Cat. No.: HY-N1937

Copy Link Print Information

Pristimerin

(Synonyms: Celastrol methyl ester)

8 Cited Publications

Customer Review

Based on 8 publication(s) in Google Scholar

Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC₅₀ of 93 nM.

For research use only. We do not sell to patients.

Purity: 99.81%
CAS No.: 1258-84-0
Formula: C₃₀H₄₀O₄
Molecular Weight:464.64

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pristimerin Chemical Structure

CAS No.: 1258-84-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC₅₀ of 93 nM.

IC₅₀ & Target

IC50: 93 nM (MGL)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	0.1 μg/mL Compound: 7	Cytotoxicity against human 1A9 cells after 3 days by SRB assay Cytotoxicity against human 1A9 cells after 3 days by SRB assay	[PMID: 14640511]
1A9	ED₅₀	0.11 μg/mL Compound: 7	Cytotoxicity against human 1A9 cells after 6 days by SRB assay Cytotoxicity against human 1A9 cells after 6 days by SRB assay	[PMID: 14640511]
1A9/ptx-10	ED₅₀	0.076 μg/mL Compound: 7	Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay	[PMID: 14640511]
1A9/ptx-10	ED₅₀	0.11 μg/mL Compound: 7	Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay	[PMID: 14640511]
A549	ED₅₀	0.31 μg/mL Compound: 7	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 14640511]
A549	IC₅₀	1.03 μM Compound: 1	Cytotoxic activity against human A549 cells incubated for 48 hrs by MTT assay Cytotoxic activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 28587825]
A549	IC₅₀	1.1 μM Compound: 1a	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34170694]
A549	IC₅₀	1.4 μM Compound: CEL01	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27647369]
A549	IC₅₀	2.6 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39106494]
Bel-7402	IC₅₀	1.16 μM Compound: 1	Cytotoxic activity against human Bel7402 cells incubated for 48 hrs by MTT assay Cytotoxic activity against human Bel7402 cells incubated for 48 hrs by MTT assay	[PMID: 28587825]
Bel-7402	IC₅₀	2.2 μM Compound: 1	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39106494]
HCT-8	ED₅₀	0.15 μg/mL Compound: 7	Cytotoxicity against human HCT8 cells after 3 days by SRB assay Cytotoxicity against human HCT8 cells after 3 days by SRB assay	[PMID: 14640511]
HeLa	IC₅₀	0.32 μM Compound: 1	Cytotoxic activity against human HeLa cells incubated for 48 hrs by MTT assay Cytotoxic activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 28587825]
HeLa	IC₅₀	3.42 μM Compound: B, triterpene quinine methide	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23395966]
HepG2	IC₅₀	0.78 μM Compound: 1	Cytotoxic activity against human HepG2 cells incubated for 48 hrs by MTT assay Cytotoxic activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 28587825]
HL-60	IC₅₀	0.2 μM Compound: 23	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21090801]
HT-29	IC₅₀	4600 ng/mL Compound: 6	Cytotoxicity against human HT-29 cells after 72 hrs by Alamar blue assay Cytotoxicity against human HT-29 cells after 72 hrs by Alamar blue assay	[PMID: 9644053]
Huh-7	CC₅₀	>6.25 μM Compound: GNF-Pf-476	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
KB	ED₅₀	0.1 μg/mL Compound: 7	Cytotoxicity against human KB cells after 3 days by SRB assay Cytotoxicity against human KB cells after 3 days by SRB assay	[PMID: 14640511]
KB	IC₅₀	0.55 μg/mL Compound: 5	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 7714534]
KB	IC₅₀	0.9 μM Compound: 1a	Antiproliferative activity against human KB cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human KB cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34170694]
L1210	IC₅₀	0.36 μg/mL Compound: 5	Cytotoxicity against mouse L1210 cells by MTT assay Cytotoxicity against mouse L1210 cells by MTT assay	[PMID: 7714534]
MCF-10A	IC₅₀	0.8 μM Compound: 1	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39106494]
MCF7	ED₅₀	0.14 μg/mL Compound: 7	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 14640511]
MCF7	IC₅₀	0.4 μM Compound: 23	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21090801]
MCF7	IC₅₀	0.87 μM Compound: B, triterpene quinine methide	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23395966]
MCF7	IC₅₀	0.9 μM Compound: 1a	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34170694]
MCF7	IC₅₀	1.57 μM Compound: CEL01	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27647369]
MCF7	IC₅₀	3 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 39106494]
MDA-MB-231	IC₅₀	0.8 μM Compound: 1a	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34170694]
P388	IC₅₀	0.12 μg/mL Compound: 5	Cytotoxicity against mouse P388 cells by MTT assay Cytotoxicity against mouse P388 cells by MTT assay	[PMID: 7714534]
PANC-1	IC₅₀	1.49 μM Compound: CEL01	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27647369]
PC-3	ED₅₀	0.23 μg/mL Compound: 7	Cytotoxicity against human PC3 cells after 3 days by SRB assay Cytotoxicity against human PC3 cells after 3 days by SRB assay	[PMID: 14640511]
RPMI-8226	IC₅₀	16.6 μM Compound: 3	Growth inhibition of human RPMI8226 cells Growth inhibition of human RPMI8226 cells	[PMID: 18164197]
SGC-7901	IC₅₀	0.63 μM Compound: 1	Cytotoxic activity against human SGC7901 cells incubated for 48 hrs by MTT assay Cytotoxic activity against human SGC7901 cells incubated for 48 hrs by MTT assay	[PMID: 28587825]
SW982	IC₅₀	1.28 μM Compound: B, triterpene quinine methide	Cytotoxicity against human SW982 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SW982 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23395966]
T cell line	CC₅₀	2.4 μM Compound: 1a	Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 32822186]
T cell line	IC₅₀	1202 nM Compound: 1a	Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay	[PMID: 32822186]
U-87MG ATCC	ED₅₀	0.17 μg/mL Compound: 7	Cytotoxicity against human U87MG cells after 3 days by SRB assay Cytotoxicity against human U87MG cells after 3 days by SRB assay	[PMID: 14640511]

In Vitro

Pristimerin inhibits the activity of purified MGL with an IC₅₀ of 93±8 nM and that of non-purified MGL (cell lysates of MGL-transfected HeLa cells) with an IC₅₀ of 398±68 nM. Pristimerin inhibits MGL through a mechanism that is rapid, reversible and non-competitive. The binding of pristimerin to MGL might be strengthened by formation of a polar interaction with a regulatory cysteine, possibly Cys²⁰⁸^[1]. Pristimerin inhibits HFLS-RA and HUVEC cell viability in a dose- and time-dependent manner. Pristimerin decreases VEGF-induced autophosphorylation of VEGFR2 and attenuates the activation of the VEGF-induced VEGFR2-mediated signaling pathway ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pristimerin inhibits inflammation and tumor angiogenesis. Pristimerin significantly reduces vessel density in synovial membrane tissues of inflamed joints and reduces the expression of pro-angiogenic factors in sera, including TNF-α, Ang-1, and MMP-9^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1258-84-0
Appearance Solid
Molecular Weight 464.64
Formula C₃₀H₄₀O₄
Color Orange to reddish brown
SMILES

C[C@](C1=CC=C(C(C)=C2O)C3=CC2=O)(CC[C@]4(C)[C@@]5([H])C[C@@](C(OC)=O)(C)CC4)[C@]5(CC[C@]13C)C
Synonyms

Celastrol methyl ester
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All WBCell Proliferation/Viability AssayCell Imaging/StainingHistological Imaging/StainingRT-PCR

Sort by:

Journal Impact Factor

Phytomedicine

Effect of pristimerin on apoptosis through activation of ROS/ endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer. [Abstract]

2021 Jan;80:153399. PMID: 33202325
Cell Death Discov

The glycolytic enzyme PFKFB3 alleviates DNA damage and chondrocyte senescence in osteoarthritis. [Abstract]

2025 Dec 8. PMID: 41360766

Pristimerin purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2025 Dec 8. [Abstract]

Representative blots and c densitometric quantification of p65 and p-p65 in cultured cells transfected with siPFKFB3 in the presence of NF-κB inhibitors, Pristimerin (500 nM) and IT901 (150 nM).

Pristimerin purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2025 Dec 8. [Abstract]

Senescence-associated β-galactosidase (SA-β-Gal) staining in the presence of Pristimerin (500 nM) and IT901.

Pristimerin purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2025 Dec 8. [Abstract]

mRNA expression of pro-inflammatory factors in cultured chondrocytes transfected with siPFKFB3 in the presence of Pristimerin (500 nM).
Drug Des Devel Ther

The Therapeutic Potential of Pristimerin in Osteoarthritis: Mechanistic Insights from in vitro and in vivo Studies. [Abstract]

2024 Nov 27:18:5445-5459. PMID: 39628956

Pristimerin purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2024 Nov 27:18:5445-5459. [Abstract]

Cells were treated by several concentrations Pristimerin (pri) (25 nM, 50 nM, 100 nM, 200 nM, 400 nM, 800 nM, 1000 nM, 2000 nM, 4000 nM) for 24 or 48 h. The viability of chondrocytes was assessed by CCK-8 assay.

Pristimerin purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2024 Nov 27:18:5445-5459. [Abstract]

Hematoxylin-Eosin staining of cartilage Pristimerin (Pri) (200 nM) treatment.
Drug Des Devel Ther

Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo. [Abstract]

2020 Oct 9;14:4189-4203. PMID: 33116407
Int Immunopharmacol

Pristimerin reduces dextran sulfate sodium-induced colitis in mice by inhibiting microRNA-155. [Abstract]

2021 May:94:107491. PMID: 33770552
Mol Med Rep

Pristimerin ameliorates colitis‑induced intestinal mucosal injury by inhibiting intestinal epithelial necroptosis. [Abstract]

2025 Jun;31(6):153. PMID: 40211716
Naunyn Schmiedebergs Arch Pharmacol

Pristimerin enhances erastin-induced ferroptosis in AML cells via the ATF3/SLC7A11 axis. [Abstract]

2026 May 29. PMID: 42209734
Vet Microbiol

Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virus. [Abstract]

2025 Sep 15:310:110730. PMID: 40976146

Solvent & Solubility

In Vitro:

DMF : 25 mg/mL (53.81 mM; Need ultrasonic)

DMSO : 20 mg/mL (43.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1522 mL

10.7610 mL

21.5220 mL

5 mM

0.4304 mL

2.1522 mL

4.3044 mL

10 mM

0.2152 mL

1.0761 mL

2.1522 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2 mg/mL (4.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

HFLS-RA (5 × 10³ cells/mL) or HUVECs (1 × 10⁴ cells/well) are seeded in 96-well plates and cultured in normal growth medium for 24 h. The cells are then incubated with different Pristimerin concentrations (0, 0.125, 0.25, 0.5 μM). The effects of Pristimerin on HUVECs viability are determined under VEGF-induced conditions. Cell viability is quantified by MTT assay. At 4 h before the end of the culture period, 30 μL of MTT solution (5.0 mg/mL) is added to each well. Cells without Pristimerin or VEGF served as a vehicle control^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Rat: Pristimerin is dissolved in DMSO (0.4%) and intraperitoneally injected daily into Male Sprague-Dawley rats in the experimental group (low-dose group, 0.40 mg/kg of body weight; high-dose group, 0.80 mg/kg of body weight) from day 11 to day 24 of immunization. The model group received vehicle (DMSO, 0.4%), and the normal control group received normal saline (NS). Methotrexate (positive control) is suspended in NS and orally administered in the autoimmune phase at an interval of 5 days^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. King AR, et al. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol. 2009 Oct 30;16(10):1045-52. [Content Brief]

[2]. Deng Q, et al. Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways. Int Immunopharmacol. 2015 Dec;29(2):302-13. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / DMF	1 mM	2.1522 mL	10.7610 mL	21.5220 mL	53.8051 mL
	5 mM	0.4304 mL	2.1522 mL	4.3044 mL	10.7610 mL
	10 mM	0.2152 mL	1.0761 mL	2.1522 mL	5.3805 mL
	15 mM	0.1435 mL	0.7174 mL	1.4348 mL	3.5870 mL
	20 mM	0.1076 mL	0.5381 mL	1.0761 mL	2.6903 mL
	25 mM	0.0861 mL	0.4304 mL	0.8609 mL	2.1522 mL
	30 mM	0.0717 mL	0.3587 mL	0.7174 mL	1.7935 mL
	40 mM	0.0538 mL	0.2690 mL	0.5381 mL	1.3451 mL
DMF	50 mM	0.0430 mL	0.2152 mL	0.4304 mL	1.0761 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Pristimerin

Anti-Infection Compound Library

Natural Product Library

Antibacterial Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Lipid Metabolism Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Pristimerin

Biological Activity

Chemical Information

Publications (8)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Pristimerin

Anti-Infection Compound Library

Natural Product Library

Antibacterial Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Lipid Metabolism Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Pristimerin

Biological Activity

Chemical Information

Publications (8)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Pristimerin Related Classifications

HY-N1937 Related Classifications